Acrivon Therapeutics Ownership | Who Owns Acrivon Therapeutics?


OverviewForecastFinancialsChart

Acrivon Therapeutics Ownership Summary


Acrivon Therapeutics is owned by 2.79% institutional investors, 20.57% insiders, and 76.64% retail investors. Ra capital management is the largest institutional shareholder, holding 21.69% of ACRV shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.73% of its assets in Acrivon Therapeutics shares.

ACRV Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAcrivon Therapeutics2.79%20.57%76.64%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management8.34M21.69%$15.10M
Sands capital ventures2.12M5.52%$3.84M
Wellington management group llp888.13K2.31%$1.61M
Vanguard group698.86K1.81%$1.68M
Renaissance634.17K1.64%$1.53M
Acadian asset management581.21K1.51%$1.40M
Acorn capital advisors405.24K1.05%$733.48K
Ubs group348.54K0.90%$839.98K
Jane street group342.07K0.89%$824.39K
Two sigma investments, lp319.20K0.83%$577.76K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sands capital ventures2.12M0.84%$3.84M
Acorn capital advisors405.24K0.37%$733.48K
Ra capital management8.34M0.19%$15.10M
Aaf wealth management10.68K0.01%$25.73K
Xtx topco35.95K0.00%$65.08K
Renaissance634.17K0.00%$1.53M
Acadian asset management581.21K0.00%$1.40M
Algert global44.65K0.00%$81.00K
Two sigma investments, lp319.20K0.00%$577.76K
Bridgeway capital management22.90K0.00%$41.45K

Top Buyers

HolderShares% AssetsChange
Acadian asset management581.21K0.00%489.20K
Two sigma investments, lp319.20K0.00%138.03K
Two sigma advisers, lp136.50K0.00%103.90K
Goldman sachs group119.42K-99.68K
Vanguard group698.86K-72.71K

Top Sellers

HolderShares% AssetsChange
Perceptive advisors---5.36M
Ubs group348.54K0.00%-334.68K
Hrt financial lp---145.90K
Blackrock funding, inc. /de205.12K--125.83K
Dafna capital management---112.41K

New Positions

HolderShares% AssetsChangeValue
Algert global44.65K0.00%44.65K$81.00K
Marex group10.00K0.00%10.00K$24.10K
Optima capital278.000.00%278.00$670.00

Sold Out

HolderChange
Wells fargo & company/mn-141.00
True wealth design-176.00
Sterling capital management-198.00
Gamma investing-287.00
Amalgamated bank-378.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20257-84.78%1,075,876-93.85%20.14%3-81.25%1-94.44%
Sep 30, 202510-80.77%655,031-96.32%10.08%5-80.77%3-81.25%
Jun 30, 202551-15.00%17,796,335-20.97%461.34%254.17%16-23.81%
Mar 31, 20254-93.10%14,129,412-38.60%361.01%--100.00%1-92.86%
Dec 31, 20245915.69%23,249,5511.26%611.68%3129.17%14-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv545.54K1.73%131.90K
HBM Healthcare Investments AG Ord527.15K1.68%-39.51K
Vanguard US Total Market Shares ETF387.41K1.24%-
Lago Erie SICAV194.44K0.62%194.44K
Vanguard Institutional Extnd Mkt Idx Tr161.39K0.51%7.31K
Fidelity Small Cap Index129.48K0.41%-
iShares Biotechnology ETF125.85K0.40%-
iShares Russell 2000 Value ETF108.94K0.35%-
Fidelity Extended Market Index102.36K0.32%2.55K
A4Investments SICAV SIF ACCI IlanaA2EURH84.78K0.27%30.72K

Recent Insider Transactions


DateNameRoleActivityValue
Jan 14, 2026Blume-Jensen Peter President and CEOBuy$82.12K
Jan 14, 2026Levy Adam D. Chief Financial OfficerBuy$15.00K
Jan 13, 2026Devroe Eric Chief Operating OfficerBuy$17.22K
Apr 30, 2025PERCEPTIVE ADVISORS LLC-Sell$617.41K
May 01, 2025PERCEPTIVE ADVISORS LLC-Sell$400.51K

Insider Transactions Trends


DateBuySell
2026 Q13-
2025 Q4--
2025 Q3--
2025 Q2-5
2025 Q1--

ACRV Ownership FAQ


Who Owns Acrivon Therapeutics?

Acrivon Therapeutics shareholders are primarily institutional investors at 2.79%, followed by 20.57% insiders and 76.64% retail investors. The average institutional ownership in Acrivon Therapeutics's industry, Biotech Stocks , is 381.47%, which Acrivon Therapeutics falls below.

Who owns the most shares of Acrivon Therapeutics?

Acrivon Therapeutics’s largest shareholders are Ra capital management (8.34M shares, 21.69%), Sands capital ventures (2.12M shares, 5.52%), and Wellington management group llp (888.13K shares, 2.31%). Together, they hold 29.51% of Acrivon Therapeutics’s total shares outstanding.

Does Blackrock own Acrivon Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Acrivon Therapeutics.

Who is Acrivon Therapeutics’s biggest shareholder by percentage of total assets invested?

Sands capital ventures is Acrivon Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.84% of its assets in 2.12M Acrivon Therapeutics shares, valued at 3.84M$.

Who is the top mutual fund holder of Acrivon Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Acrivon Therapeutics shares, with 1.73% of its total shares outstanding invested in 545.54K Acrivon Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools